Delivery Order 36F79724D0185-36C24525N0305
Award Date
1/8/25
Potential Completion Date
1/13/25
Potential Value
$22K
Federal Agency
Veterans Integrated Service Network 5
Awardee
Amicus Therapeutics US, LLC
Ultimate Awardee
Amicus Therapeutics, Inc.
NAICS Category
325412 - Pharmaceutical Preparation Manufacturing
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Philadelphia, PA 19104, USA
Solicitation Procedures
Multiple Award, Fair Opportunity
Number Of Offers Received
1
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
The U.S. Department of Veterans Affairs (VA) awarded a $21,089.47 firm fixed price delivery order contract to Amicus Therapeutics US, LLC, a subsidiary of Amicus Therapeutics, Inc. The contract is for the supply of GALAFOLD 123 MG, an enzyme replacement therapy for the treatment of Fabry disease. This delivery order was placed under Amicus Therapeutics US, LLC's Federal Supply Schedule (FSS) contract 36F79724D0185, which has a ceiling value of $13,024,630 and a period of performance through...
This federal contract award is for the delivery of GALAFOLD 123 MG to the Department of Veterans Affairs (VA). The contract was awarded to Amicus Therapeutics US, LLC, a subsidiary of the biopharmaceutical company Amicus Therapeutics, Inc. The $21,089.47 firm fixed price delivery order has a completion date of November 19, 2024 and was awarded on November 14, 2024. Amicus Therapeutics US, LLC holds a Federal Supply Schedule (FSS) contract (36F79724D0185) with the VA's Pharmaceuticals and Drugs...
This federal contract award is for the delivery of Galafold (migalastat) 123mg capsules, an enzyme replacement therapy for the treatment of Fabry disease. The contract, valued at $63,268.41, was awarded by the U.S. Department of Veterans Affairs (VA) to Amicus Therapeutics US, LLC, a subsidiary of the biopharmaceutical company Amicus Therapeutics, Inc. The contract is a firm fixed-price delivery order issued under Amicus Therapeutics US, LLC's Federal Supply Schedule (FSS) contract with the...
This is a federal contract award to Amicus Therapeutics US, LLC, a subsidiary of Amicus Therapeutics, Inc., for the delivery of Galafold (migalastat), an enzyme replacement therapy used to treat Fabry disease. The contract, valued at $261,090.68, is a firm-fixed-price delivery order awarded by the U.S. Department of Veterans Affairs (VA) under the Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB). The contract has an ultimate completion date of November 14, 2025. Amicus...
This federal contract award was issued by the U.S. Department of Veterans Affairs (VA) to Amicus Therapeutics US, LLC, a subsidiary of Amicus Therapeutics, Inc. The contract is a $21,089.47 firm fixed price delivery order for the supply of Galafold (migalastat), an FDA-approved enzyme replacement therapy used to treat Fabry disease, a rare genetic disorder. The contract has an ultimate completion date of October 7, 2024 and was awarded on October 3, 2024. The contract is not set aside and Amicus...
This federal contract award, with the ID 36F79724D0185|36C24525N0364, was issued by the U.S. Department of Veterans Affairs (VA) to the prime contractor Amicus Therapeutics US, LLC. The contract is a delivery order for the pharmaceutical product Galafold 123 mg, an enzyme replacement therapy used to treat Fabry disease. Amicus Therapeutics US, LLC, a subsidiary of Amicus Therapeutics, Inc., has an existing Federal Supply Schedule (FSS) contract (36F79724D0185) with the VA under the...
The Department of Veterans Affairs Veterans Health Administration awarded a firm fixed price delivery order to Amicus Therapeutics US, LLC, a subsidiary of publicly traded biopharmaceutical company Amicus Therapeutics, Inc. The order, valued at $21,089.47, is for the specialty medication Galafold (migalastat) to treat Fabry disease. The delivery order was placed against Amicus Therapeutics US, LLC's five-year Federal Supply Schedule (FSS) contract for Pharmaceuticals and Drugs (FSS-61-IB), a...
This is a delivery order awarded by the U.S. Department of Veterans Affairs (VA) to Amicus Therapeutics US, LLC, a subsidiary of Amicus Therapeutics, Inc. The order, valued at $21,089.47, is for the pharmaceutical product Galafold 123 mg, an enzyme replacement therapy used to treat Fabry disease, a rare genetic disorder. The order is a firm fixed-price contract with no set-aside designation. Amicus Therapeutics US, LLC holds a Pharmaceuticals and Drugs Federal Supply Schedule contract...
The federal contract award (ID: 36F79724D0185|36C24525N0568) is a firm fixed-price delivery order for the pharmaceutical product Galafold 123 mg, an enzyme replacement therapy used to treat Fabry disease. The contract, with a ceiling value of $21,891.21 and an ultimate completion date of April 16, 2025, was awarded to the prime contractor Amicus Therapeutics US, LLC, a subsidiary of Amicus Therapeutics, Inc. The contract is placed under the Pharmaceuticals and Drugs Federal Supply Schedule...
This federal contract award (ID: 36F79724D0185|36C24925N0624) was issued by the Department of Veterans Affairs (VA) to Amicus Therapeutics US, LLC, a biopharmaceutical company focused on rare genetic diseases. The $65,673.63 firm fixed-price delivery order is for the pharmaceutical product Galafold (migalastat) 123 mg, an enzyme replacement therapy used to treat Fabry disease. The award is part of Amicus Therapeutics US, LLC's $13,024,630 Federal Supply Schedule (FSS) contract (36F79724D0185)...